Last reviewed · How we verify
Desloratadine 5 mg
At a glance
| Generic name | Desloratadine 5 mg |
|---|---|
| Also known as | Clarinex, SCH 034117, Clarinex, SCH 34117, Clarinex; SCH 34117 |
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Desloratadine in Patients With Ulcerative Colitis (PHASE2)
- Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine (PHASE3)
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study (PHASE4)
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED) (PHASE4)
- Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836) (PHASE4)
- The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609) (PHASE3)
- A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) (PHASE4)
- Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desloratadine 5 mg CI brief — competitive landscape report
- Desloratadine 5 mg updates RSS · CI watch RSS
- Organon and Co portfolio CI